Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Insulin Resistance 1Diabetes Mellitus, Type 2 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1238Docetaxel 1227Oxaliplatin 1184Capecitabine 1178Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 640Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Biguanides × Clear all
NCT02497638 2021-04-19

LIGAND

University Health Network, Toronto

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT02475499 2016-03-14

Incretin-based Drugs and Pancreatic Cancer

Canadian Network for Observational Drug Effect Studies, CNODES

Completed
886,172 enrolled
Gastrointestinal

Diabetes Mellitus, Type 2, Pancreatic Neoplasms

NCT00948402 2009-10-14

PED/PEA-15 Protein, PCOS, Obesity, Insulin Sensitivity Indexes, Metformin, Oral Contraceptives

Federico II University

Phase 3 Completed
20 enrolled

Insulin Resistance, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡